Jefferies Financial Group’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-11,000
Closed -$58.2K – 1272
2026
Q2
$58.2K Hold
11,000
– – ﹤0.01% 1566
2026
Q1
$41.2K Sell
11,000
-2
-0% -$7 ﹤0.01% 1653
2025
Q4
$33.1K Buy
11,002
+2
+0% +$5 ﹤0.01% 1785
2025
Q3
$20.9K Hold
11,000
– – ﹤0.01% 1411
2025
Q2
$15.6K Sell
11,000
-29,200
-73% -$39.5K ﹤0.01% 1229
2025
Q1
$61.5K Sell
40,200
-500
-1% -$1.07K ﹤0.01% 1509
2024
Q4
$101K Buy
40,700
+29,200
+254% +$72.7K ﹤0.01% 1456
2024
Q3
$13.2K Hold
11,500
– – ﹤0.01% 1379
2024
Q2
$12.6K Hold
11,500
– – ﹤0.01% 1354
2024
Q1
$14.3K Hold
11,500
– – ﹤0.01% 1534
2023
Q4
$12.1K Sell
11,500
-25,051
-69% -$76.4K ﹤0.01% 1622
2023
Q3
$250K Buy
36,551
+10,000
+38% +$85.5K ﹤0.01% 1280
2023
Q2
$275K Sell
26,551
-390,000
-94% -$3.53M ﹤0.01% 1351
2023
Q1
$3.37M Buy
+416,551
New +$5.29M 0.03% 484

Other funds holding ACRS

Jefferies Financial Group's ACRS Position: Q3 2026 in Review

Jefferies Financial Group sold out of Aclaris Therapeutics (ACRS) in Q3 2026, closing a stake of 11,000 shares — an estimated $58.2K sold.

Jefferies Financial Group first reported a position in ACRS in Q1 2023 and held it in 14 quarters. The position peaked at $3.37M in Q1 2023. 166 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.

  • Jefferies Financial Group reported no remaining Aclaris Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 11,000 Aclaris Therapeutics shares in Q3 2026, an estimated $58.2K.
  • Jefferies Financial Group first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 14 quarters.
  • Jefferies Financial Group's Aclaris Therapeutics position peaked at $3.37M in Q1 2023.
  • 166 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.